Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Error occurred: cannot get document summary
Dysplastic Barrett's esophagus in cirrhosis: a treatment dilemma.
Raftopoulos SC, Efthymiou M, May G, Marcon N.
Am J Gastroenterol. 2011 Sep;106(9):1724-6. doi: 10.1038/ajg.2011.174. No abstract available.
Related citations
Is the lymphoma risk reduced in viral hepatitis? A cirrhotic patient with triple malignancies.
Doganay L, Kiziltas S, Colak Y, Gulluoglu M, Tuncer I.
Am J Gastroenterol. 2011 Sep;106(9):1719-20; author reply 1720. doi: 10.1038/ajg.2011.214. No abstract available.
Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model.
Kim BK, Kim do Y, Han KH, Park JY, Kim JK, Paik YH, Lee KS, Chon CY, Ahn SH.
Am J Gastroenterol. 2011 Sep;106(9):1654-62, 1730. doi: 10.1038/ajg.2011.160. Epub 2011 Jun 21. Erratum in: Am J Gastroenterol. 2011 Sep;106(9):1730.
Small intestinal bacterial overgrowth and Helicobacter pylori: can they be cause of thrombocytopenia in patients with chronic liver disease?
Savarino E, Assandri L, Giannini EG, Savarino V.
Am J Gastroenterol. 2011 Jun;106(6):1171-2; author reply 1172. No abstract available.
The multi-dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers.
Bajaj JS, Wade JB, Gibson DP, Heuman DM, Thacker LR, Sterling RK, Stravitz RT, Luketic V, Fuchs M, White MB, Bell DE, Gilles H, Morton K, Noble N, Puri P, Sanyal AJ.
Am J Gastroenterol. 2011 Sep;106(9):1646-53. doi: 10.1038/ajg.2011.157. Epub 2011 May 10.
3-nitro-tyrosine as a peripheral biomarker of minimal hepatic encephalopathy in patients with liver cirrhosis.
Montoliu C, Cauli O, Urios A, ElMlili N, Serra MA, Giner-Duran R, González-Lopez O, Del Olmo JA, Wassel A, Rodrigo JM, Felipo V.
Am J Gastroenterol. 2011 Sep;106(9):1629-37. doi: 10.1038/ajg.2011.123. Epub 2011 Apr 12.
Evening administration of long-acting beta-blockers for primary prophylaxis in cirrhosis: an effective strategy.
Talwalkar JA.
Am J Gastroenterol. 2011 Mar;106(3):545; author reply 545. No abstract available.
Editorial: Exercise for NAFLD: does intensity matter?
Conjeevaram HS, Tiniakos DG.
Am J Gastroenterol. 2011 Mar;106(3):470-5.
Physical activity recommendations, exercise intensity, and histological severity of nonalcoholic fatty liver disease.
Kistler KD, Brunt EM, Clark JM, Diehl AM, Sallis JF, Schwimmer JB; NASH CRN Research Group.
Am J Gastroenterol. 2011 Mar;106(3):460-8; quiz 469. Epub 2011 Jan 4.
Effects of branched-chain amino acids supplementation in patients with cirrhosis and a previous episode of hepatic encephalopathy: a randomized study.
Les I, Doval E, García-Martínez R, Planas M, Cárdenas G, Gómez P, Flavià M, Jacas C, Mínguez B, Vergara M, Soriano G, Vila C, Esteban R, Córdoba J.
Am J Gastroenterol. 2011 Jun;106(6):1081-8. Epub 2011 Feb 15.
Editorial: rifaximin and minimal hepatic encephalopathy.
Butterworth RF.
Am J Gastroenterol. 2011 Feb;106(2):317-8.
Viral factors and outcomes of chronic HBV infection.
Huang Y, Lok AS.
Am J Gastroenterol. 2011 Jan;106(1):93-5.
Potential precipitating factors of esophageal variceal bleeding: a case-control study.
Liao WC, Hou MC, Chang CJ, Lee FY, Lin HC, Lee SD.
Am J Gastroenterol. 2011 Jan;106(1):96-103. Epub 2010 Sep 7.
Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study.
Berman K, Tandra S, Vuppalanchi R, Ghabril M, Sandrasegaran K, Nguyen J, Caffrey H, Liangpunsakul S, Lumeng L, Kwo P, Chalasani N.
Am J Gastroenterol. 2011 May;106(5):899-906. Epub 2010 Dec 21. Erratum in: Am J Gastroenterol. 2011 Jul;106(7):1405. Vuppalanch, Raj [corrected to Vuppalanchi, Raj].
Rifaximin improves psychometric performance and health-related quality of life in patients with minimal hepatic encephalopathy (the RIME Trial).
Sidhu SS, Goyal O, Mishra BP, Sood A, Chhina RS, Soni RK.
Am J Gastroenterol. 2011 Feb;106(2):307-16. Epub 2010 Dec 14.
Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C.
Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group.
Am J Gastroenterol. 2011 May;106(5):884-93. Epub 2010 Dec 7.
Thrombocytopenia associated with chronic liver disease: effects of rifaximin on platelet count.
Kalambokis G, Tsianos EV.
Am J Gastroenterol. 2010 Dec;105(12):2705-7. No abstract available.
Association between the various mutations in viral core promoter region to different stages of hepatitis B, ranging of asymptomatic carrier state to hepatocellular carcinoma.
Yin J, Xie J, Liu S, Zhang H, Han L, Lu W, Shen Q, Xu G, Dong H, Shen J, Zhang J, Han J, Wang L, Liu Y, Wang F, Zhao J, Zhang Q, Ni W, Wang H, Cao G.
Am J Gastroenterol. 2011 Jan;106(1):81-92. Epub 2010 Oct 19.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on